Skip to main content

IL-32 expression is an independent prognostic marker for gastric cancer

Medical Oncology volume 30, Article number: 472 (2013) Cite this article

Abstract

A strong link between inflammation and gastrointestinal cancer has been demonstrated. Interleukin (IL)-32 is a recently described pro-inflammatory cytokine characterized by the induction of nuclear factor kappa B (NF-κB) activation. We investigated whether IL-32 expression has clinical significance in gastric cancer. A total of 182 gastric cancer patients who received curative gastrectomy were enrolled in our study. IL-32 expression was detected by immunohistochemistry, and the correlation between clinicopathological features and IL-32 expression was analyzed. Tumor depth and lymph node metastases developed more frequently in IL-32-positive gastric cancer patients than those who were negative for IL-32 expression (p < 0.01). Lymphatic- and venous invasion in the IL-32-positive group were more severe than in cancer cells lacking IL-32 expression (p < 0.05). Multivariate analysis demonstrated that IL-32 is one of the prognostic markers (p < 0.03) for gastric cancer, in addition to nodal involvement and tumor depth. IL-32 positivity significantly affected clinicopathological factors. Thus, IL-32 expression in gastric cancer may serve as a preferential metastatic condition that allows cells to escape host antitumor immunity. Pro-inflammatory cytokines induce immunosuppression in a paracrine manner, thereby facilitating the metastasis of tumor cells.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Noh SH, Hyung WJ, Cheong JH. Minimally invasive treatment for gastric cancer: approaches and selection process. J Surg Oncol. 2005;90:188–93.

    PubMed  Article  Google Scholar 

  2. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol. 1996;23:360–8.

    PubMed  CAS  Google Scholar 

  3. Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Modern surgery for gastric cancer-Japanese perspective. Scand J Surg. 2006;95:232–5.

    PubMed  CAS  Google Scholar 

  4. Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol. 2006;41:929–42.

    PubMed  Article  Google Scholar 

  5. Kobayashi M, Okabayashi T, Sano T, Araki K. Metastatic bone cancer as a recurrence of early gastric cancer: characteristics and possible mechanisms. World J Gastroenterol. 2005;11:5587–91.

    PubMed  Google Scholar 

  6. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24:4347–55.

    PubMed  Article  Google Scholar 

  7. Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, Röcken C. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29:2364–71.

    PubMed  Article  Google Scholar 

  8. Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010;13:212–21.

    PubMed  Article  CAS  Google Scholar 

  9. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995;95:207–12.

    PubMed  Article  CAS  Google Scholar 

  10. Morisaki T, Katano M, Ikubo A, Anan K, Nakamura M, Nakamura K, Sato H, Tanaka M, Torisu M. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol. 1996;63:234–9.

    PubMed  Article  CAS  Google Scholar 

  11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    PubMed  Article  CAS  Google Scholar 

  12. Ben-Baruch A. Inflammation-associated immune suppression incancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.

    PubMed  Article  CAS  Google Scholar 

  13. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–36.

    PubMed  Article  CAS  Google Scholar 

  14. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, Turato G, Lokar-Oliani K, Papi A, Zuin R, Sfriso P, Balestro E, Dinarello CA, Saetta M. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:894–901.

    PubMed  Article  CAS  Google Scholar 

  15. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity. 2005;22:131–42.

    PubMed  CAS  Google Scholar 

  16. Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6:131–7.

    PubMed  Article  CAS  Google Scholar 

  17. Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 2009;180:769–79.

    PubMed  Article  CAS  Google Scholar 

  18. Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem. 2009;284:17868–76.

    PubMed  Article  CAS  Google Scholar 

  19. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd english edition. Gastric Cancer. 1998;1:10–24.

    PubMed  Article  Google Scholar 

  20. Hong J, Bae S, Kang Y, Yoon D, Bai X, Chan ED, Azam T, Dinarello CA, Lee S, Her E, Rho G, Kim S. Suppressing IL-32 in monocytes impairs the induction of the pro-inflammatory cytokines TNF alpha and IL-1beta. Cytokine. 2010;49:171–6.

    PubMed  Article  CAS  Google Scholar 

  21. Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, Apte RN. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011;186:3462–71.

    PubMed  Article  CAS  Google Scholar 

  22. Kobayashi H, Lin PC. Molecular characterization of IL-32 in human endothelial cells. Cytokine. 2009;46:351–8.

    PubMed  Article  CAS  Google Scholar 

  23. Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, Kim JH, Kim EJ, Park DK, Kim SH. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol. 2008;18:1606–12.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Grant-in-Aid for Scientific Research (KAKENHI) (No 21591707). The authors would like to thank the pathologists for their valuable technical assistance and facilitating the collection of patient information.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Digestive Surgery Surgical Oncology, Kagoshima University School of Medicine, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, JAPAN

    Sumiya Ishigami, Takaaki Arigami, Yasuto Uchikado, Tetsuro Setoyama, Yoshiaki Kita, Ken Sasaki, Hiroshi Okumura, Hiroshi Kurahara, Yuko Kijima, Aya Harada, Shinichi Ueno & Shoji Natsugoe

Authors
  1. Sumiya Ishigami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaaki Arigami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuto Uchikado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuro Setoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiaki Kita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroshi Kurahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuko Kijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aya Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shinichi Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shoji Natsugoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sumiya Ishigami.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ishigami, S., Arigami, T., Uchikado, Y. et al. IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30, 472 (2013). https://doi.org/10.1007/s12032-013-0472-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0472-4

Keywords

  • IL-32
  • Pro-inflammatory cytokine
  • Prognostic marker
  • Lymph node
  • Gastric cancer